Menü
Dieses Wertpapier wird aktuell nicht bei uns gehandelt
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

Summit Hotel Properties Inc.

WKN: A1H7RF / Name: Summit Htl Prti / Aktie / REITs / Small Cap /

4,92 €
-1,20 %

Summit Materials Inc.

WKN: A14QAG / Symbol: SUM / Name: Summit Materials / Aktie / Baumaterial / Mid Cap /

50,50 €
1,00 %

Sun Summit Minerals Corp.

WKN: A402FR / Name: Sun Summit Minerals Corp. / Aktie / ? /

0,093 €
-3,13 %

Here's Why Summit Midstream (SMC) is Poised for a Turnaround After Losing 17.2% in 4 Weeks
Here's Why Summit Midstream (SMC) is Poised for a Turnaround After Losing 17.2% in 4 Weeks

Summit Midstream Partners, LP (SMC) has been beaten down lately with too much selling pressure. While the stock has lost 17.2% over the past four weeks, there is light at the end of the tunnel as it

Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet

Shares of Summit Therapeutics PLC (SMMT) have gained 8.8% over the past four weeks to close the last trading session at $17.54, but there could still be a solid upside left in the stock if

All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy

Summit Therapeutics PLC (SMMT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

Key Points